Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus rating of "Moderate Buy" from six research firms, with one hold rating and five buy ratings.
• Several hedge funds have increased their stakes in Niagen Bioscience, reflecting growing institutional interest, with ownership now at 15.41% of the company's stock.
• The company reported earnings of $0.04 per share, exceeding estimates, with revenue of $31.12 million for the last quarter, indicating robust financial performance.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.42.

Several equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Niagen Bioscience in a report on Wednesday, October 8th. Finally, HC Wainwright boosted their target price on shares of Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Monday, August 11th.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds have recently modified their holdings of the stock. Financial Consulate Inc. purchased a new position in shares of Niagen Bioscience in the third quarter worth $33,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience in the third quarter worth $144,000. CWM LLC purchased a new position in shares of Niagen Bioscience in the third quarter worth $246,000. BSW Wealth Partners purchased a new position in shares of Niagen Bioscience in the third quarter worth $793,000. Finally, Silverberg Bernstein Capital Management LLC purchased a new position in shares of Niagen Bioscience in the third quarter worth $1,169,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

Niagen Bioscience Price Performance

Shares of NASDAQ:NAGE opened at $7.51 on Wednesday. Niagen Bioscience has a 1-year low of $3.39 and a 1-year high of $14.69. The company has a market capitalization of $598.95 million, a P/E ratio of 35.76 and a beta of 2.13. The firm's 50 day simple moving average is $9.05 and its two-hundred day simple moving average is $9.63.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The business had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.